Clinically significant bleeding can occur as a consequence of surgery, trauma, obstetric
complications, anticoagulation, and a wide variety of disorders of hemostasis. As the causes …

Tranexamic acid (TXA) is an anti-fibrinolytic agent that acts by inhibiting plasminogen
activation and fibrinolysis. Although its first clinical use dates back more than 50 years, this …

Tranexamic acid (TXA) is an antifibrinolytic agent commonly used for the treatment or
prevention of bleeding. Indications for TXA are diverse, including heavy menstrual bleeding …

The publication of the Clinical Randomization of an Antifibrinolytic in Significant
Hemorrhage-2 (CRASH-2) study and its intense dissemination prompted a renaissance for …

Objectives We review the evidence for tranexamic acid (TXA) for the treatment and
prevention of bleeding caused by surgery, trauma and bleeding disorders. We highlight …

Uncontrolled massive bleeding with subsequent derangement of the coagulation system is a
major challenge in the management of both surgical and seriously injured patients. Under …

Intravenous tranexamic acid (TXA) reduces death because of bleeding in patients with
trauma and postpartum haemorrhage. However, in some settings intravenous injection is not …

Blood loss and subsequent transfusions are associated with major morbidity and mortality.
The use of antifibrinolytics can reduce blood loss in cardiac surgery, trauma, orthopedic …

Abstract Purpose In this Continuing Professional Development module, we review the
practical pharmacology of tranexamic acid and its clinical use in trauma, obstetrics, and …

Background Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal
deaths every year, most of which occur in low-and middle-income countries. Tranexamic …